Gritstone bio, Inc. (GRTS)
| Previous Close | 3.0400 |
| Open | 3.0100 |
| Bid | 3.1700 x 1800 |
| Ask | 3.1800 x 800 |
| Day's Range | 3.0100 - 3.1950 |
| 52 Week Range | 1.7100 - 6.1000 |
| Volume | |
| Avg. Volume | 1,236,331 |
| Market Cap | 264.688M |
| Beta (5Y Monthly) | 0.52 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.5440 |
| Earnings Date | Mar 08, 2023 - Mar 13, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.75 |
- Simply Wall St.
Investors in Gritstone bio (NASDAQ:GRTS) have unfortunately lost 66% over the last three years
It is doubtless a positive to see that the Gritstone bio, Inc. ( NASDAQ:GRTS ) share price has gained some 32% in the...
- GlobeNewswire
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
EMERYVILLE, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that the company’s Board of Directors granted two employees nonqualified stock options to purchase an aggregate of 28,000 shares of its common stock with an exercise price of $3.67, which is equal to the closing price of Gritstone’s common stock on January 9, 2023, the date of the grant. These stock
- GlobeNewswire
Gritstone bio to Participate in Upcoming Investor Conferences
EMERYVILLE, Calif., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that management will participate in the following investor conferences. B. Riley Securities' 3rd Annual Oncology Conference (Fireside Chat)Date and Time: Thursday, January 19, 2023 at 12:30pm ETPresenter: Andrew Allen, M.D., Ph.D., Co-founder, President, and Chief Executive Officer 2023 BIO CEO & Inve
